ATLANTA -- New research presented at ACR Convergence, the American College Rheumatology's annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral ...

Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...

Please provide your email address to receive an email when new articles are posted on . Among a cohort of postmenopausal women randomly assigned to romosozumab or alendronate, larger improvements in ...

Please provide your email address to receive an email when new articles are posted on . Romosozumab as a first treatment produces ‘substantial gains’ in hip and lumbar spine bone mineral density ...

About EVENITY® (romosozumab) EVENITY is a bone-forming monoclonal antibody. It is designed to work by inhibiting the activity of sclerostin, which simultaneously results in increased bone formation ...

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). These data ...

Peter L. Salgo, MD: Based on all this, I know you said there were data. There were trials. I’ve gotten this written down. I’m not making this up. There’s the FRAME study, and there’s the ARCH study.

The investigational humanized monoclonal antibody romosozumab (Amgen and UCB Pharma) increases bone mineral density (BMD) and bone formation and reduces bone resorption in postmenopausal women with ...

AUSTIN, Texas – One year of romosozumab (Evenity) followed by 1 year of denosumab (Prolia, Xgeva) was associated with improved bone mineral density (BMD) and lower fracture incidence compared with 2 ...

Latest guidelines on the treatment of osteoporosis have been released that include new recommendations for the use of romosozumab (Evenity, Amgen) in postmenopausal women with severe osteoporosis, but ...

Romosozumab, a recently developed sclerostin inhibitor, stimulates bone formation and inhibits bone resorption, thereby markedly increasing bone mass and reducing fracture risk. But will a red flag ...